menu search

Lecanemab Receives Priority Review Status in Japan

Lecanemab Receives Priority Review Status in Japan
TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* […] The post Lecanemab Receives Priority Review Status in Japan appeared first on... Read More
Posted: Jan 29 2023, 23:30
Author Name: forextv
Views: 112298

Search within

Pages Search Results: